Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07791758
PHASE1/PHASE2

A Phase Ib/II Clinical Study of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma

Sponsor: Nanjing Leads Biolabs Co.,Ltd

View on ClinicalTrials.gov

Summary

This study is an open-label, multi-center Phase Ib/II clinical trial evaluating the safety and efficacy of LBL-024 in combination with other drugs for the treatment of metastatic colorectal carcinoma (mCRC), aiming to evaluate the safety and efficacy of LBL-024 in combination with other drugs in the treatment of mCRC patients.

Official title: An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of LBL-024 Combination Therapy in Patients With Metastatic Colorectal Carcinoma

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

369

Start Date

2026-09-04

Completion Date

2030-09-04

Last Updated

2026-08-28

Healthy Volunteers

No

Interventions

DRUG

LBL-024 for Injection

intravenous infusion.

DRUG

Bevacizumab injection

intravenous infusion.

DRUG

Oxaliplatin injection

intravenous infusion.

DRUG

Capecitabine tablets

Oral.

DRUG

Fruquintinib Capsules

Oral.

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China